Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Non-cash Items (2020 - 2023)

Candel Therapeutics' Non-cash Items history spans 4 years, with the latest figure at $3.5 million for Q3 2023.

  • For Q3 2023, Non-cash Items rose 29.98% year-over-year to $3.5 million; the TTM value through Sep 2023 reached $3.5 million, up 29.98%, while the annual FY2022 figure was $2.9 million, 40.16% up from the prior year.
  • Non-cash Items for Q3 2023 was $3.5 million at Candel Therapeutics, down from $10.0 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $13.8 million in Q4 2020 and bottomed at $1.1 million in Q2 2021.
  • The 4-year median for Non-cash Items is $2.7 million (2022), against an average of $4.5 million.
  • The largest annual shift saw Non-cash Items tumbled 85.15% in 2021 before it soared 314.85% in 2023.
  • A 4-year view of Non-cash Items shows it stood at $13.8 million in 2020, then crashed by 85.15% to $2.1 million in 2021, then soared by 40.16% to $2.9 million in 2022, then increased by 20.93% to $3.5 million in 2023.
  • Per Business Quant, the three most recent readings for CADL's Non-cash Items are $3.5 million (Q3 2023), $10.0 million (Q2 2023), and $7.0 million (Q1 2023).